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)e aim of this study was to test antimicrobial activity of ethanol extract of Lavandula stoechas against 22 bacteria and 1 yeast.
Also, biochemical composition of the extract was investigated. A wide range of Gram-positive, Gram-negative microorganisms,
and multidrug resistant bacteria were selected to test the antimicrobial activity. As a result, the extract is observed to contain
fenchone (bicyclo[2.2.1]heptan-2-one, 1,3,3-trimethyl-, (1R)-) and camphor (+)-2-bornanone) as major components and showed
antimicrobial activity against all studied microorganisms except Escherichia coli ATCC 25922 and Klebsiella pneumoniae. )e
results of the study present that L. stoechas is active against MDR strains too.
1. Introduction
)e World Health Organization (WHO) has predicted in-
creasing antimicrobial resistance as a major threat for the
public health for the twenty-first century. In order to prevent
spreading of antibiotic resistance infections, scientists have
been conducting intensive researches to determine new
antimicrobial agents. One way to prevent antibiotic re-
sistance of microorganisms is by using new compounds that
are not based on existing antimicrobial agents.
)e Lavandula genus is an important member of family
Lamiaceae. It consists of 47 species of small evergreen shrubs
having aromatic foliage and flowers [1]. Lavandula species
are cultivated in France, Spain, and Italy. In Turkey, mainly
two species, Lavandula stoechas and Lavandula angustifolia,
and their subspecies and hybrid forms grow wildly or are
cultivated [2]. )e medicinal importance of the plant is well
documented [3, 4], and the drugs prepared from this plant
are registered in many Pharmacopeia [5]. L. stoechas L. is
used in perfumery and cosmetics [6, 7]. Anticonvulsant,
sedative, and antispasmodic activities were reported [8]. )e
essential oil (EO) of L. stoechas possesses weak antibacterial
activity [9]. It is used in folk medicine as an antispasmodic, a
sedative, and a diuretic and for rheumatic diseases [7]. )e
main purpose of this study was to investigate the antimi-
crobial activity of L. stoechas and reveal the major com-
ponents of its ethanol extracts.
2. Materials and Methods
2.1. Endemic Plant Samples. Dried flowers of L. stoechas L.
were purchased from the local market in Canakkale, Turkey,
and identified by Dr. Mustafa Eray Bozyel.
2.2. Disk Diffusion Test. Plant samples were dried after
collection and ground into small pieces with a grinder.
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Ground L. stoechas samples were shaken in ethanol (Sigma-
Aldrich) at 125 rpm for 2 days at room temperature. After
that, all the mixture was filtrated through Whatman no. 1
filter paper into evaporation flasks. Filtrates were evaporated
by a rotary evaporator (Buchi R3) at 45°C [10, 11]. Finally,
the remnants were collected and weighed. 5.83, 23.4, and
35.1mg samples were prepared. )e activity of the extract
was tested against 22 bacteria and 1 yeast, where most of the
strains were standard; nostandard strains were isolated from
food and the MDR strains were clinical isolates. Non-
standard strains were identified in Ankara University, De-
partment of Biology and Duzce University, Department of
medical. All bacterial strains were incubated at 37°C for
24 hours; however, Candida albicans was incubated at 27°C
for 48 hours [11]. Each bacteria and yeast were inoculated
into 0.9% sterile saline solution and adjusted to 0.5
McFarland standard, in order to standardize inocula to
contain about 108 cfu·mL−1 for bacteria and 107 cfu·mL−1 for
C. albicans [11]. )e antimicrobial activity of ethanol extract
of L. stoechas was tested by the disk diffusion test, as
mentioned before [12]. Firstly, Mueller–Hinton agar (BD
Difco, USA) was poured into 90mm sterile Petri dish in
order to reach a meant depth of 4.0mm± 0.5mm. )e
extracts were loaded on 6mm Oxoid Antimicrobial Sus-
ceptibility Test Disks. Disks were left to dry overnight at 30°C
in sterile conditions in order to prevent any remaining of
solvent, which may interfere with the results. After that,
prepared microorganisms, which were inoculated into saline
solution, were streaked on the surface of Petri dishes. )ese
plates were left to dry for 5minutes at room temperature in
aseptic conditions [12]. Next, disks were tightly applied to
the surface of plates. Finally, these plates were incubated, and
inhibition zone diameters were recorded [12].
Preculturing conditions for all microorganisms are as
mentioned previously[13].
2.3. Broth Dilution Test. Broth dilution method for mini-
mum inhibitory concentration (MIC) determination as
described previously was employed [14]. Serial 2-fold di-
lutions were made to obtain a concentration range of
0.07–35.9 µg/mL. )e MIC was defined as the lowest con-
centration of extract inhibiting any visible bacterial growth.
All tests were conducted in triplicates.
2.4. GC-MS Analysis. For the identification of chemical
components, each sample was analyzed by Agilent GC
6890N-Agilent MS 5973 equipped with HP5-MS capillary
column (30m∗ 0.25mm; coating thickness 0.25 μm). Ana-
lytical conditions were an injector temperature of 350°C;
carrier gas helium at 1mL/min; injection mode: split, split
ratio 10 :1; volume injected: 1 μL of sample in ethanol ex-
tract; oven temperature programmed from 40°C to 350°C at
4°C/min; pressure: 48.2 kPa; and split flow: 9.9mL/min. )e
MS scan conditions were a transfer line temperature of
280°C, an interface temperature of 280°C, and an ion source
temperature of 230°C. Identification of the components was
conducted by matching the retention times against National
Institute of Standards and Technology (NIST Mass
Spectrometry DATA CENTER) data library, and crosscheck
was applied with previously published data [15, 16] )e
chemical components found to be higher than 1% were
accepted as the major components, and the list of these
components and information regarding them are given in
Table 1.
2.5. Controls. Empty sterile disks and extraction solvent
(ethanol) were used as negative controls. Ciprofloxacin and
gentamicin used as pozitif controls (Table 2).
2.6. Statistics. )e statistical analysis was executed using a
parametric method, the one-way analysis of variance
(ANOVA), with a significance level of 0.05. In order to put
forward any correlation between concentration and anti-
microbial activity, Pearson correlation coefficient was cal-
culated. All statistical analysis were conducted by using R
Studio, version 3.3.2 [17].
3. Results and Discussion
)e diameters of inhibition zones, which were measured in
millimeters, are given in Table 3 as the mean values of three
parallels with standard errors. No activities were observed
for the negative controls. Furthermore, statistical analysis
proved that there are no significant differences between the
activities of three parallels of each extract volumes (p> 0.05).
On the other hand, a weak positive correlation is observed
between the activities of extracts and the volumes tested,
with a Pearson correlation coefficient of 0.3239.
In addition, the results of broth dilution test (MIC
values) are given in Table 4.
According to Table 3, L. stoechas has antimicrobial ac-
tivity against all studied microorganisms except Escherichia
coli ATCC 25922 and Klebsiella pneumoniae. )ree of them
have high susceptibility (15–25mm); seven of them have
moderate susceptibility (14–10mm); and eleven of them
have low susceptibility (9–7mm). L. stoechas shows anti-
microbial activity against all tested MDR bacteria. )ese
results are important since antimicrobial activity of this
species were determined against large range of Gram-
negative and Gram-positive bacteria.
According to GC-MS results, fenchone (bicyclo[2.2.1]
heptan-2-one, 1,3,3-trimethyl (1R)-), and camphor (+)-2-
bornanone) are mainly found in the composition of L.
stoechas ethanol extract. Similar results were obtained when
compared with previous researches [18–20] (Figure 1).
)e antimicrobial effect of the plant is known from
previous investigations, but there is no broad-spectrum
study like this [18, 20]. It has also been reported for the
first time that the plant’s ethanol extract is effective against
multidrug-resistant microorganisms, which is one of the
most important health hazards in the world [21].
Acinetobacter species, particularly Acinetobacter bau-
mannii, have become significant pathogens especially in the
nosocomial setting. A. baumannii has progressively been
implicated in serious nosocomial infections, including
bloodstream infection (BSI), nosocomial and ventilator-related
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Table 1: )e major chemical components of L. stoechas according to the GC-MS analysis.
No. Retention time Compound name Formula Molecular weight (g/mol) Area (%)
1 14.529 Eucalyptol C10H18O 154.249 6.22
2 16.940 Bicyclo[2.2.1]heptan-2-one, 1,3,3-trimethyl-, (1R)- C10H16O 152.233 18.81
3 19.163 (+)-2-Bornanone C10H16O 152.233 8.64
4 22.138 Fenchyl acetate C12H20O2 196.286 1.10
5 24.593 Bornyl acetate C12H20O2 196.286 3.40
6 26.015 Myrtenyl acetate C12H18O2 194.270 5.18
7 30.067 Benzaldehyde, 2-hydroxy-4-methyl- C8H8O2 136.148 1.64
8 31.687 Cubedol C15H26O 222.366 1.10
9 32.350 Cubedol C15H26O 222.366 1.08
10 32.854 Bicyclo[3.1.1]hept-3-en-2-one, 4,6,6-trimethyl- C10H14O 150.218 1.40
11 33.844 Acetic acid, 4a-methyl-1,2,3,4,4a,5,6,7-octahydronaphthalen-2-yl ester 1.42
12 34.749 Veridiflorol C15H26O 222.366 4.50
13 35.121 Viridiflorol C15H26O 222.366 2.99
14 37.869 Unknown — — 1.02
15 39.683 Andrographolide C20H30O5 350.449 1.15
16 48.039 Palmitic acid C16H32O2 256.424 2.48
17 52.456 Behenic alcohol C22H46O 326.600 1.06
18 75.553 Tetrapentacontane C54H110 759.451 1.48
19 77.908 Tetrapentacontane C54H110 759.451 1.37
20 82.903 Tetrapentacontane C54H110 759.451 4.84
21 86.068 Tetrapentacontane C54H110 759.451 4.83
22 91.031 Tetrapentacontane C54H110 759.451 2.53
23 91.398 Stigmast-5-en-3-ol, (3.beta.)- C29H50O 414.707 3.25
Table 2: Pozitif controls (inhibition zones in mm).
Ciprofloxacin Gentamicin
B. subtilis DSMZ 1971 36 30
C. albicans DSMZ 1386 — —
E. aerogenes ATCC 13048 30 23
E. durans 24 14
E. faecalis ATCC 29212 19 13
E. faecium 28 28
E. coli ATCC 25922 — 20
K. pneumoniae 30 22
L. innocula 18 13
L. monocytogenes ATCC 7644 20 28
P. aeruginosa DSMZ 50071 28 15
P. fluorescens P1 19 12
S. enteritidis ATCC 13075 36 24
S. infantis 24 24
S. Kentucky 34 13
S. typhimurium SL 1344 35 23
S. aureus ATCC 25923 22 24
S. epidermidis DSMZ 20044 34 25
—: no activity observed.
Table 3: Disk diffusion test result for L. stoechas (inhibition zones in mm).
5.83mg loaded disk 23.4mg loaded disk 35.1mg loaded disk
Bacillus subtilis DSMZ 1971 11.00± 0.00 13.00± 0.00 14.00± 0.58
Candida albicans DSMZ 1386 7.00± 0.00 9.00± 0.00 11.00± 0.00
Enterobacter aerogenes ATCC 13048 — — 8.00± 0.00
Escherichia coli — — 8.00± 0.00
Escherichia coli ATCC 25922 — — —
Enterococcus durans — 10.00± 0.00 11.00± 0.00
Enterecoccus faecalis ATCC 29212 7.00± 0.00 9.00± 0.00 11.00± 0.00
Enterecoccus faecium 11.00± 0.58 16.00± 0.58 15.00± 1.15
Klebsiella pneumoniae — — —
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Table 3: Continued.
5.83mg loaded disk 23.4mg loaded disk 35.1mg loaded disk
Listeria innocua — 8.00± 0.00 10.00± 0.00
Listeria monocytogenes ATCC 7644 9.00± 0.00 14.00± 1.15 13.00± 0.58
Pseudomonas aeruginosa DSMZ 50071 — 8.00± 0.00 10.00± 0.00
Pseudomonas fluorescens P1 7.00± 0.00 9.00± 0.00 13.00± 0.00
Staphylococcus aureus 10.00± 0.00 10.00± 0.00 14.00± 0.58
Staphylococcus aureus ATCC 25923 12.00± 0.58 13.00± 0.00 18.00± 0.00
Salmonella enteritidis ATCC 13076 7.00± 0.00 9.00± 0.00 10.00± 0.00
Staphylococcus epidermidis DSMZ 20044 15.00± 0.00 19.00± 0.58 20.00± 0.00
Salmonella infantis — — 10.00± 0.00
Salmonella kentucky — 7.00± 0.00 10.00± 0.00
Salmonella typhimurium SL1344 8.00± 0.58 — 10.00± 1.15
Acinetobacter baumannii MDR — 10.00± 0.00 11.00± 0.00
Proteus vulgaris MDR 10.00± 1.15 14.00± 1.15 11.00± 1.15
Streptococcus pneumoniae MDR 10.00± 0.00 14.00± 1.15 13.00± 0.58
—: no inhibition.
Table 4: MIC values for L. stoechas (MIC values in µg/mL).
MIC
Bacillus subtilis DSMZ 1971 35.9
Candida albicans DSMZ 1386 35.9
Enterobacter aerogenes ATCC 13048 —
Escherichia coli —
Escherichia coli ATCC 25922 —
Enterococcus durans 35.9
Enterecoccus faecalis ATCC 29212 35.9
Enterecoccus faecium 17.95
Klebsiella pneumoniae —
Listeria innocua 35.9
Listeria monocytogenes ATCC 7644 35.9
Pseudomonas aeruginosa DSMZ 50071 35.9
Pseudomonas fluorescens P1 35.9
Staphylococcus aureus 17.95
Staphylococcus aureus ATCC 25923 17.95
Salmonella enteritidis ATCC 13076 35.9
Staphylococcus epidermidis DSMZ 20044 8.98
Salmonella infantis —
Salmonella kentucky 35.9
Salmonella typhimurium SL1344 35.9
Acinetobacter baumannii MDR 35.9
Proteus vulgaris MDR 35.9
Streptococcus pneumoniae MDR 35.9
—: no inhibition.
15,071,599
10.0 20.0 30.0 40.0 50.0 60.0 70.0
(min)
80.0 90.0 100.0 110.0 120.0 130.0 137
Figure 1: GC-MS chromatography of L. stoechas.
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pneumonia, and meningitis. )ese infections are particularly
common in critically ill patients, with mortalities as high as
40–64% for pneumonia and 17–46% for BSI [22].)e extensive
use of broad-spectrum antibiotic agents within hospitals has led
to the rapid emergence of multidrug-resistant (MDR) A.
baumannii strains. Only a few antimicrobial agents are active
against MDR A. baumannii infections [22]. In our study, we
observed 11mm of inhibition zone against A. baumannii
(MDR) strain. Moreover, we have found 14mm of inhibition
zones against Proteus vulgaris (MDR) and Streptococcus
pneumoniae (MDR) strains. Our results present that L. stoechas
is active against MDR strains too.
Previous studies tested the antimicrobial activity of L.
stoechas and found MIC values between 0 and 6500 µg/mL
[23]. When the result of this study were compared with the
results of the previous study, it may be observed that the
MIC values obtained in our study were much lower, which is
better. )e reason of this difference should be related with
the strains used in two studies. Although B. subtilis, S.
aureus, S. typhimurium, E. coli, and C. albicans were used in
both studies, the strains were different. Only L. mono-
cytogenesATCC 7644 were common in these two studies but
the MIC values were different. )is difference could be
related with the composition of extracts which were directly
affected by the environment; those plant samples were
collected.
Another previous study was tested the antimicrobial
activity of two subspecies of L. stoechas. )e only common
microorganism used in our study and this previous study
was C. albicans. )ey observed a MIC value> 100 µg/mL for
both subspecies, which are quite higher than our results [24].
But this difference is logical since the plant samples, C.
albicans strain, and collection area were different.
Ez Zoubi et al. [25] tested the antimicrobial activity of the
essential oil of L. stoechas against E. coli, K. pneumoniae,
Proteus mirabilis, and P. aeruginosa. As a result, they ob-
served MIC values between 2.5 and 10 µg/mL. Although the
strains of these microorganisms were not defined, the dif-
ference in the MIC values between this study and our study
was mainly due to using different types of extracts, namely,
essential oil and ethanol extracts.
4. Conclusion
Our study clearly presents that L. stoechas should have a
possible medicinal uses, especially against MDR bacteria.
However, further researches are needed in order to analyse
the active substances and their activity mechanisms in
details.
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